GLP1R and early-onset autosomal dominant Alzheimer disease: GLP-1 RAs, such as exenatide, may thus represents a disease modifying intervention for Alzheimer’s disease, or adjuvant secondary treatment for symptom progression through regulation of chronic inflammation.